Trastuzumab in various forms in combination with chemotherapy has been successful in targeting ERBB2 overexpression in ERBB2+ breast cancer and improving survival as a standard first-line therapy for more than a decade (Molina et al, 2005; Cobleigh et al,1999). This evidence concerns the gene ERBB2 and breast carcinoma.